Related Experiment Videos
Vaccines for herpes simplex virus infections.
1University of Washington, Harborview Medical Center, Seattle 98104, USA. viralimm@u.washington.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|February 28, 2006
Summary
Developing new herpes simplex virus (HSV) vaccines is crucial as current antivirals do not cure infections. Promising vaccine candidates, including a glycoprotein D2 subunit vaccine, are advancing in clinical trials to combat HSV-1 and HSV-2.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Herpes simplex virus (HSV) types 1 and 2 cause significant medical issues.
- Antiviral drugs manage symptoms but do not cure HSV infections or prevent transmission.
- Immune system modulation presents a potential strategy to reduce HSV disease burden.
Purpose of the Study:
- To review current research on prophylactic and therapeutic HSV vaccines.
- To highlight vaccines in clinical trials or with novel mechanisms.
- To discuss strategies for preventing and treating HSV infections.
Main Methods:
- Review of scientific literature on HSV vaccine development.
- Focus on vaccines that have entered clinical trials.
- Analysis of novel vaccine compositions and proposed mechanisms of action.
Main Results:
- A subunit glycoprotein D2 vaccine, adjuvanted with alum and monophosphoryl lipid A, showed efficacy in preventing HSV-2 infection and disease in a Phase III trial.
- Confirmatory clinical trials for this glycoprotein D2 vaccine are ongoing.
- Other vaccine approaches under investigation include attenuated live or replication-incompetent HSV-2 strains and CD8 T-cell targeted therapies.
Conclusions:
- Vaccination represents a promising avenue for controlling HSV infections.
- Novel vaccine candidates are demonstrating potential in clinical and preclinical studies.
- Further research and clinical trials are essential to develop effective HSV vaccines.